Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Repros Therapeutics Inc. (RPRX) Report Updated: Oct 17, 2016 | Print This Page

Get more stock ratings by Louis Navellier

Repros Therapeutics Inc. (RPRX)

Rating: Hold Volatility: Aggressive
Total Grade: C Industry: Pharmaceuticals
Competitors: MRK,JNJ,HSKA,CYNA

Stock Analysis

Rating: Monthly View

October November December January February March April May June July August September

Rating: Weekly View

This Week: C down no change
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

Repros Therapeutics Inc.© quotemedia

Company Profile

Repros Therapeutics Inc., a biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders for male and female in the United States. Its product portfolio includes Androxal, an oral therapy, which is in Phase III clinical trials for the treatment of low testosterone due to secondary hypogonadism; and Proellex that is in Phase IIB clinical trials for the treatment of symptoms associated with uterine fibroids, as well as in Phase II clinical trial for the treatment of endometriosis. The company has a license agreement with the National Institutes of Health to develop and commercialize Proellex. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas.